A Phase 2 interventional study of ATx201 and ATx201 GEL Vehicle in Impetigo, sponsored by UNION therapeutics. Completed at 16 sites in South Africa. Open to participants aged 9 Months to 70 Years. Per ClinicalTrials.gov, last updated 2018-07-31.
Sponsored by UNION therapeutics · Phase 2, Interventional, and Treatment
This is a Phase 2 study evaluating the safety, tolerability, systemic exposure, and activity of topical ATx201 GEL (2% and 4%) treatment for 1, 2, or 5 days in outpatients with primary nonbullous or bullous impetigo.
30 studies on the registry are indexed under Impetigo; 3 are open to participants now.
This study's enrollment of 210 is below the median of 255 across 24 interventional studies indexed under Impetigo.
Browse Impetigo studies →UNION therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ATx201
Drug: ATx201
Drug: ATx201 · Other: ATx201 GEL Vehicle
Drug: ATx201 · Other: ATx201 GEL Vehicle
Other: ATx201 GEL Vehicle
ATx201 GEL
Vehicle
Incidences of Adverse Events and Laboratory Parameters
incidences of adverse events reports and changes in significant laboratory parameters
Time frame: 14 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ATX201
UNION therapeutics